[New Premium Alert Inside] FSD Pharma Inc. (NASDAQ:HUGE) Read This!

Attention: New Alert ! Today's trading session FSD Pharma Inc. (NASDAQ: HUGE) Do NOT Miss This... 10XProTrader Member, This is Kevin Vander with "10XProTrader" delivering you your new premium alert for Today's 4/30 trading session which is FSD Pharma Inc. (NASDAQ: HUGE), another company, which has unique products, a competitive stronghold, and targets market opportunities that generate millions today and billions by the end of this decade.   FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) closed at $0.43 today, and with a market cap of roughly $19.6 million, it presents a value proposition that could deliver significant near and long-term gains. That's not a presumption based on blind ambition. Your 10x team has scoured the news wires, read the company's SEC filings, and stayed focused on developments, including the two announced last week that indicate this under-the-radar company may make it onto the screens of the investor heard sooner rather than later.  While that's expected, we want to make sure you look at FSD Pharma for all the right reasons. Yes, through subsidiaries like Lucid-MS, FSD Pharma is building a portfolio of innovative assets and biotech solutions to treat challenging neurodegenerative and metabolic disorders. No one should be discounting the massive opportunity that particular asset can deliver. From a marketing, licensing, or partnership perspective, and the fact that it has shown promise in treating the underlying mechanism of multiple sclerosis in preclinical models, it can indeed be a significant value driver. Many Value Drivers...But Investors Should Focus On UNBUZZD™  Frankly, that asset alone can justify the entire market cap on a comparative basis to others in that space. While investors would be wise to consider the investment proposition based on the Lucid-MS value contributions, the bigger prize and certainly the more near-term one may result from licensing to Celly Nutrition (Celly Nu), its proprietary formulation of natural ingredients, vitamins, and minerals that help with liver and brain function to quickly relieve individuals from the effects of alcohol consumption. This product, branded as UNBUZZD™, is being heralded by many as a game-changer to drinkers wanting or needing "rapid alcohol detoxification."  This product is not "too good to be true." UNBUZZD™ is the real deal, scientifically formulated to expedite alcohol metabolism, aid in recovery from alcohol consumption, and enhance mental alertness. And check this out: UNBUZZD™ is backed by industry luminaries like Gerry David (former CEO of Celsius Holdings, Inc.) and John Duffy (with extensive experience at Coca-Cola). These are not just names, but individuals with a proven track record of success in the industry. Talent like that doesn't join losing teams. Instead, they combine with other talent and, more importantly, products that can transform from an ambitious idea into billions in sales, which could very well be the case in a rapidly growing functional beverage market segment.  The best news is that the plan to do so is in progress. On April 25th, FSD Pharma pointed to a Celly Nu press release announcing a strategic partnership with Six+One, a purpose-driven branding, advertising, and production agency based in New York City. That groundbreaking partnership is expected to significantly enhance UNBUZZD™ market image, presence, and position ahead of its near-term full-scale launch in the United States.  A Who's Who Leadership Team That's Generated Billions In Sales  Why is this relationship a big deal? For many reasons, but here's one we like the most: Six+One is known for its innovative work with brands like Vitaminwater and Body Armor, both of which were acquired by The Coca-Cola Company after the expert hand of Six+One helped lead growth trajectories. Because Six+One has been tasked to create a comprehensive brand development program for UNBUZZD™, including establishing a brand personality, visual identity creation, packaging design, and building the company website, history may very well repeat. In fact, if there is one thing the company and investors can bet on, it's that Six+One definitely has a proven formula for making small brands bigger. In some cases, exponentially. That's not all working to unleash the inherent value and potential of UNBUZZD™.  Celly Nu added additional brand and marketing firepower in April, announcing a partnership with BevSource, another sector powerhouse that provides beverage development and production solutions. This relationship intends to streamline production and distribution processes for UNBUZZD™ to ensure seamless market penetration across different strategic branding and marketing formats. BevSource also has an impressive collaboration history. They were part of the team developing distinguished brands like Celsius, Kill Cliff, and WG Brewing Company. That supports the premise for their being an ideal partner for Celly Nutrition in this venture.  Here's the best part...expect the combined work of those two, in addition to the other in-house projects, to generate agreements with major retailers and e-commerce platforms to drive product placements and maximize revenue-generating opportunities.  UNBUZZD™ Is A Trailblazer In A Massive Functional Beverage Sector  In other words, early investors in this potentially trailblazing product could be ideally positioned to capture the value from idea, to market penetration, to a potentially massive sale to a global beverage company. Remember, large brands no longer develop- they acquire. And with a brand and product as potentially disruptive as UNBUZZD™, there could be several big players on the bid to ensure they have interest in the products commanding the most valuable real estate in the world: SHELF SPACE!  In this case, UNBUZZD™ could score plenty. Reports indicate that U.S. consumer demand for "functional beverages" is soaring, as evidenced by the [$175 billion functional beverage segment in 2022]( which is expected to reach over $339 billion by 2030. That's not all. Targeting the dietary supplements market also puts a massive opportunity in play;[ it generated over $167 billion last year](. Factoring those markets into the equation, the revenue-generating opportunities in play for UNBUZZD™ can be far higher than its primary target market, the "hangover cure products market," suggests. Said more directly, by selling into multiple verticals, the sales growth trajectory for UNBUZZD™ could steepen to a nearly straight line higher. That's speculative but not overly so.  FSD Pharma is, after all, doing things others aren't. That includes submitting its Clinical Trial Application (CTA) for a planned Phase-1b clinical trial to Assess the Safety and Efficacy of UNBUZZD™ in Healthy Volunteers in an Induced State of Alcohol Intoxication (METAL-1 TRIAL). That milestone is the culmination of months of work by the FSD team and its expert advisors, who have conceptualized and designed this clinical trial to assess the safety and efficacy of UNBUZZD™ on people who drink alcohol. If results post as expected, it could support UNBUZZD™ earning the lion's share of the massive revenue pie.  Here's something else to factor. While competitors are trying to market a brand, UNBUZZD™ may ultimately emerge as the only brand and product able to boast proven benefits with FDA endorsement. That can make an already strong competitive position nearly insurmountable to those trying to poach market share.  UNBUZZD™ Is Making Strong Statements Without Regulatory Objection  By the way, UNBUZZD™ has already made bold statements, with the FDA not objecting. Remember, the FDA is not a forgiving agency when it comes to inaccurate and deceptive marketing. Thus, an accurate appraisal of UNBUZZD™ must include the value of comparative advantages, which in this case are differences that can position it as an undisputed market leader. UNBUZZD™ product statements made that others may be hesitant to include in marketing are:  "Product restores mental alertness" "Product promotes mental health" "Product promotes alcohol metabolism by the body's natural dehydrogenase liver enzymes" "Product accelerates the metabolism of alcohol by ADH and ALDH" "Product replenishes cofactors necessary for alcohol metabolism by the liver enzymes" "Product replenishes cofactors necessary for alcohol metabolism" "Product enhances mental alertness and replenishes cofactors for alcohol metabolism" "Product enhances mental alertness and accelerates the rate of alcohol metabolism" "Product supports faster recovery from alcohol inebriation"  Noting those intrinsics, the bullish company forecasts could actually prove to be conservative. In a recent presentation, the team behind UNBUZZD™ forecasted 2024 revenues to reach about $1.6 million. That's for starters. Year-over-year revenues are forecast to grow 287% in 2025, 176% in 2026, and 141% in 2027, culminating in expected sales of over $41 million by the end of that period. While investors should appreciate that topline growth, the bottom line is important as well. Not expecting to disappoint there, the team expects to produce operating profit in 2026, followed by roughly $13 million dropping to the bottom line in 2027 as scale efficiencies take root.  A Valuation Disconnect Worth Seizing  If that forecast turns to actual, it could generate a tsunami of interest in HUGE stock. And with only about 40 million shares outstanding and insider ownership of roughly 20% reducing the trading float to roughly 34 million, it won't take much to move the valuation models higher. And remember, even incremental updates on the clinical trial and distribution deals may be plenty to support, and as important, sustain an increase in HUGE's share price.  10X Subscribers, here's the bottom line: when appraising the FSD Pharma value proposition, keep this in mind: UNBUZZD™ is more than an excellent product; it's a trailblazer led by management, advisory, brand, and marketing teams that have generated billions in value for other brands. And with an arsenal of evidence supporting that UNBUZZD™ may uniquely exploit a virtually untapped market opportunity in a massive “alcohol detox” functional beverage sector, history may very well repeat. With that in mind, and especially ahead of that potential, investors would be wise to consider seizing this value opportunity sooner rather than later. Pay very close attention to your email inbox, your next alert is just around the corner. Yours for greater gains, Kevin Vander Publisher, 10XProTrader.com Investment Research You are receiving this e-mail as part of your subscription to 10XProTrader. Please do not reply to this e-mail as this address is not monitored. Our Customer Service team is available Monday - Friday between 9:00 AM and 5:00 PM ET. © 2023 10XProTrader.com. All Rights Reserved. Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular inves∙tment situation. N∙o communication by our employees to you should be deemed as personalized financial advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers, prior or during our reporting on the company. © 2023 10XProTrader.com, All Rights Reserved. 10XProTrader is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or inve∙stment for any specific individual. This communication is a paid a∙dvertisement. 10XProTrader.com and/or its subsidiaries and/or affiliates ("Company," "we," or "us") have been compensated $20,000 USD to disseminate this communication. Please note that we do not trade any securities that we profile. We do not hold positions in stocks we profile. We do not accept stock as a form of payment for our profiles. Please review the full disc∙laimer at [( for important information about this advertisement. © 2023 10XProTrader. All rights reserved., 340 Royal Poinciana Way Suite 317, 33480, Palm Beach, United States You may [unsubscribe]( or [change your contact details]( at any time.